Matthew Wilson, MD
Allergy · Huntington, WVNPI 1891726295
Payments from drug & device makers
Across 891 payments — averaging $377.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$230K
- GSK$96K
- CSL Behring$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Optinose US, Inc.$1K
- Pfizer$1K
- plus $3K from 18 others
What the payments were for
- Consulting fees$4,3454%
- Speaking & faculty fees$90,52581%
- Travel & lodging$9761%
- Food & beverage$16,26014%
- Education$2560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 152 | $230,183 |
| GSK | 283 | $96,160 |
| CSL Behring | 86 | $2,429 |
| Regeneron Healthcare Solutions, Inc. | 84 | $1,828 |
| Optinose US, Inc. | 35 | $1,388 |
| Pfizer | 69 | $1,302 |
| Novartis | 57 | $876 |
| Genentech USA, Inc. | 40 | $709 |
| Boehringer Ingelheim | 28 | $348 |
| Sanofi | 19 | $335 |
| Amgen | 13 | $177 |
| AbbVie | 4 | $84 |
| Alk-abello, Inc | 4 | $79 |
| Kaleo, Inc. | 5 | $59 |
| Galderma Laboratories, L.p. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Integra Lifesciences Corporation | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| Incyte Corporation | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Merck | 1 | $15 |
| LEO Pharma Inc. | 1 | $14 |
| Convatec Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 79 | $345,038 |
| NucalaMepolizumab | 72 | $287,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 252 | $217,019 |
| Spiriva RespimatTiotropium Bromide | 176 | $150,278 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $137,703 |
| XolairOmalizumab | 49 | $125,749 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $122,970 |
| Breo ElliptaFluticasone/Vilanterol | 164 | $97,204 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $85,179 |
| TezspireTezepelumab-Ekko | 17 | $70,011 |
| Dupixent SyringeDupilumab | 15 | $58,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 237 | $51,860 |
| SymbicortBudesonide/Formoterol Fumarate | 135 | $43,229 |
| Advair HfaFluticasone Propion/Salmeterol | 80 | $36,005 |
| DuleraMometasone/Formoterol | 47 | $21,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $96,160 | $617,076521 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid | $26 | $208,14926 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $348 | $155,975188 claims |
| CSL BehringHizentra | $2,429 | $137,70314 claims |
| AstraZenecaTezspire, Symbicort | $230,183 | $113,240152 claims |
| MerckDulera | $15 | $21,56747 claims |
| Optinose US, Inc.Xhance | $1,388 | $10,83314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in West Virginiaon file to place this against a meaningful peer group, so we don't.
Other allergy in Huntington
- Joan LynchHuntington$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.